Companies › 4D Molecular Therapeutics
5 active drug programs in 10 registered trials: 5 Phase 1, 3 Phase 3, 2 Phase 2; Ophthalmology, Respiratory, Metabolic and endocrine; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 4D-150 AAV-based gene therapy delivering miRNA targeting VEGF-C and codon-optimized aflibercept s | VEGFA, VEGFC, VEGFR2 | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Diabetic Macular Edema … | Mar 2027 |
| 4D-710 AAV gene therapy delivering human CFTR with regulatory domain deletion (CFTRΔR) | CFTR | Phase 2 | Cystic Fibrosis Lung | Jun 2027 |
| 4D-110 AAV gene therapy delivering codon-optimized human CHM gene via AAV5 capsid variant (4D-R10 | CHM | Phase 1 | Choroideremia | May 2027 |
| 4D-125 AAV5-delivered codon-optimized human RPGR transgene | RPGR | Phase 1 | X-Linked Retinitis Pigmentosa | May 2029 |
| 4D-310 AAV gene therapy encoding codon-optimized human GLA transgene | GLA | Phase 1 | Fabry Disease | Jun 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05197270 | 4D-150 | Phase 1 | Neovascular (Wet) Age-Related Macular Degeneration | Ophthalmology | Mar 2027 |
| NCT04483440 | 4D-110 | Phase 1 | Choroideremia | Ophthalmology | May 2027 |
| NCT05248230 | 4D-710 | Phase 2 | Cystic Fibrosis Lung | Respiratory | Jun 2027 |
| NCT06864988 | 4D-150 | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | Ophthalmology | Jun 2027 |
| NCT07064759 | 4D-150 | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | Ophthalmology | Nov 2027 |
| NCT07867080 | 4D-150 | Phase 3 | Diabetic Macular Edema (DME) | Ophthalmology | Jan 2029 |
| NCT05930561 | 4D-150 | Phase 2 | Diabetic Macular Edema | Ophthalmology | Feb 2029 |
| NCT04517149 | 4D-125 | Phase 1 | X-Linked Retinitis Pigmentosa | Ophthalmology | May 2029 |
| NCT05629559 | 4D-310 | Phase 1 | Fabry Disease | Metabolic and endocrine | Jun 2030 |
| NCT04519749 | 4D-310 | Phase 1 | Fabry Disease | Metabolic and endocrine | Jun 2030 |
Cash and short-term investments of $361m on 2026-06-30; operating cash outflow about $280m a year; runway about 16 months at that burn, to Oct 2027; 2 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Ocugen Opus Genetics Beacon Therapeutics Annexin Pharmaceuticals ProQR Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.